Left ventricular mass assessment by CMR; how to define the optimal index.

about

Left ventricular mass assessment by CMR; how to define the optimal index.

Item

http://www.wikidata.org/entity/Q39975379

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Left ventricular mass assessment by CMR; how to define the optimal index.

@en

Left ventricular mass assessment by CMR; how to define the optimal index.

@nl

type

Item

label

Left ventricular mass assessment by CMR; how to define the optimal index.

@en

Left ventricular mass assessment by CMR; how to define the optimal index.

@nl

prefLabel

Left ventricular mass assessment by CMR; how to define the optimal index.

@en

Left ventricular mass assessment by CMR; how to define the optimal index.

@nl

P1476

Left ventricular mass assessment by CMR; how to define the optimal index.

@en

P2093

E E van der Wall

http://www.w3.org/2001/XMLSchema#string

H M Siebelink

http://www.w3.org/2001/XMLSchema#string

J J Bax

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac remodelling: concentric versus eccentric hypertrophy in strength and endurance athletes

Rationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertension

Cardiomyopathies: a revolution in molecular medicine and cardiac imaging.

Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest doubleheterozygosity?

Diagnostic significance of gadolinium-DTPA (diethylenetriamine penta-acetic acid) enhanced magnetic resonance imaging in thrombolytic treatment for acute myocardial infarction: its potential in assessing reperfusion.

Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy.

Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification

Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience

Drug-eluting stents: results, promises and problems.

Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy

P2888

s10554-010-9602-7

P304

469-472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1007/S10554-010-9602-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41826840

http://www.w3.org/2001/XMLSchema#string

P698

20213471

http://www.w3.org/2001/XMLSchema#string

P932

2852595

http://www.w3.org/2001/XMLSchema#string